Inmunosupresión en pacientes durante y post-infección COVID-19.

Abstract

ABSTRACT Introduction: The treatment with immunosuppresses causes patients to be at high contagious risk. It has been worrisome during the COVID-19 times, because such patients are at high contagious risk, in addition, it goes beyond the effects that the immunosuppression medicine might generate. Objective: To describe the scientific evidence, as well as, the recommendations regarding the use of immunosuppresses in patients during and after COVID-19 infection. Method: A systematic review of literature through the PRISMA bibliographic selector was conducted from March to June 2021. Results: A total 0f 20 bibliographic references were systematized, all of them focused on different illnesses that require immunosuppressive treatment, such as heart, kidney and autoimmune disease. The references indicate that immunosuppressive treatment does not complicate COVID-19 infection, therefore, it is not a risk factor in itself, however, there is a risk associated with certain diseases, especially heart disease and cancer. Conclusions: Evidence suggests that patients under immunosuppressive treatment do not show either the worst-case clinical endings or a major risk for COVID-19. Some immunosuppressive treatments are positive at stopping the progress of the COVID-19 infection, it is recommended to reduce the doses to avoid high risks of contagion. There still exists debate about whether treatment should be discontinued in some cases, such decisions must be made by the physicians in charge. The pandemic has caused many people with immunosuppressive treatment to discontinue taking their medicine, which constitutes a risk to their health. Keywords: COVID-19, immunosuppression, immunomodulatory, pre and post-infection